Metabolic pathways regulate metaplasia and cancer initiation in the pancreas

代谢途径调节胰腺化生和癌症发生

• 批准号: 10675815
• 负责人: Megan DeAnna Radyk
• 金额: $ 6.95万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10675815
• 关键词: Acinar Cell; Antioxidants; Biomass; Buffers; Cancer Etiology; Cell Culture Techniques; Cell Survival; Cell secretion; Cells; Cellular Metabolic Process; Cessation of life; Citric Acid Cycle; Coculture Techniques; Communication; Critical Pathways; Cytoprotection; Data; Detection; Development; Disease Progression; Duct (organ) structure; Ensure; Environment; Enzymes; Equilibrium; Future; G6PD gene; Gene Expression; Genes; Genetic; Genetically Engineered Mouse; Glucosephosphate Dehydrogenase; Glutamine; Glutathione; Growth; Homeostasis; Human; Immunologic Surveillance; Injury; Isotopes; K-ras mouse model; KRAS oncogenesis; KRAS2 gene; Lead; Lesion; Link; Literature; Malates; Malignant Neoplasms; Malignant neoplasm of pancreas; Metabolic; Metabolic Pathway; Metabolism; Metaplasia; Metaplastic Cell; Mouse Strains; Mus; Mutation; NADP; Neoplasms; Normal Cell; Oncogenes; Oncogenic; Organ; Oxidation-Reduction; Pancreas; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraepithelial Neoplasia; Pathway interactions; Pentosephosphate Pathway; Phenotype; Pilot Projects; Precancerous Conditions; Process; Production; Proliferating; Pyruvate; Reactive Oxygen Species; Reduced Glutathione; Repression; Research Proposals; Role; Route; Source; Stress; Survival Rate; System; Therapeutic; Tissues; Transcript; United States; Work; cancer initiation; cell type; cofactor; driver mutation; experimental study; human disease; human tissue; in vivo; innovation; insight; malic enzyme; metabolomics; mouse model; mutant; new therapeutic target; novel; novel diagnostics; pancreatic cancer model; pancreatic neoplasm; pre-clinical; premalignant; programs; response; transcriptome sequencing; transcriptomics; transdifferentiation; tumor; tumor progression; tumorigenesis

PROJECT SUMMARY Activating mutations in KRAS reprogram cell metabolism to support growth, proliferation, and survival in pancreatic cancer. However, there is little information on how KRAS-dependent alterations in metabolism contribute to premalignant states and cancer initiation. Acinar-to- ductal metaplasia (ADM) is a precancerous state essential in pancreatic ductal adenocarcinoma. During ADM, acinar cells transdifferentiate to become more duct-like and proliferative, usually in response to tissue damage. ADM is reversible but activating mutations in KRAS lead to persistent ADM and progression to neoplasia and cancer. Recent studies also show that healthy acinar cells can restrict and eliminate oncogenic KRAS-expressing cells. Based on preliminary data, I hypothesize that healthy acinar cells alter their metabolism during ADM to aid in redox homeostasis and restrict the growth of nearby oncogenic cells, thereby restricting cancer initiation. Preliminary experiments show that Glucose-6-phosphate dehydrogenase (G6pd) and Malic enzyme 1 (Me1) transcripts are significantly upregulated during ADM. G6PD is the rate limiting enzyme in the pentose phosphate pathway and ME1 converts malate to pyruvate, linking glycolytic and citric acid cycles. In addition, both G6PD and ME1 enzymes produce NADPH, which protects against redox stress. Aim 1 will focus on G6pd and Me1 and determine how redox balance and NADPH production contribute to ADM formation. Preliminary experiments show that loss of these enzymes increased the level of reactive oxygen species in acinar cells. The experiments proposed in Aim 1 use genetically engineered mouse models of pancreatic cancer, steady-state metabolomics, isotope tracing, and ex vivo primary acinar cell culture to examine the consequence on ADM and tumorigenesis when G6pd and Me1 are lost, and NADPH pools are reduced. Aim 2 will determine how metabolic redox interactions between healthy and oncogenic cells restrict ADM. Preliminary experiments suggest that healthy acinar cells secrete metabolites to inhibit adjacent KRAS- expressing cells from undergoing ADM. This aim uses inducible mouse models of KRAS-driven pancreatic cancer, metabolomics, and spatial transcriptomics. The proposed experiments will help to identify how healthy cells sense the presence of neighboring oncogenic cells and reprogram their cell state and metabolism to repress cancer initiation. Together, the aims presented in this proposal will provide new mechanistic insights on how metabolic pathways drive pancreatic cancer initiation, thereby informing future therapeutics.

项目总结 激活KRAS中的突变重新编程细胞代谢以支持生长、增殖和 胰腺癌患者的存活率。然而，关于KRAS依赖程度的信息很少 新陈代谢的改变有助于癌前状态和癌症的发生。腺泡到- 导管化生(ADM)是胰腺导管的一种癌前状态。 腺癌。在ADM期间，腺泡细胞转分化，变得更像导管和 增殖性的，通常是对组织损伤的反应。ADM是可逆的，但会激活 KRAS导致持续的ADM，并进展为肿瘤和癌症。最近的研究也 表明健康的腺泡细胞可以限制和消除致癌的KRAS表达细胞。 根据初步数据，我假设健康的腺泡细胞在 ADM有助于氧化还原动态平衡，并限制附近致癌细胞的生长，从而 限制癌症的发生。初步实验表明，葡萄糖-6-磷酸 脱氢酶(G6PD)和苹果酸酶1(ME1)转录显著上调 在ADM期间。G6PD是磷酸戊糖途径和ME1的限速酶 将苹果酸转化为丙酮酸，连接糖酵解和柠檬酸循环。此外，G6PD和 ME1酶产生NADPH，保护其免受氧化还原压力。目标1将专注于G6PD 和ME1，并确定氧化还原平衡和NADPH产生对ADM的贡献 队形。初步实验表明，这些酶的丧失增加了 腺泡细胞中的活性氧物种。目标1中提出的实验使用了基因 胰腺癌基因工程小鼠模型，稳态代谢组学，同位素示踪， 和体外原代腺泡细胞培养，以检测其对ADM和肿瘤形成的影响 当G6PD和ME1丢失时，NADPH池减少。目标2将决定如何 健康细胞和致癌细胞之间的代谢氧化还原相互作用限制了ADM。初步 实验表明，健康的腺泡细胞会分泌代谢物来抑制邻近的KRAS- 在ADM过程中表达细胞。这个目的是使用KRAS驱动的诱导性小鼠模型 胰腺癌、代谢组学和空间转录组学。拟议中的实验将 有助于识别健康细胞如何感知邻近致癌细胞的存在和 重新编程它们的细胞状态和新陈代谢，以抑制癌症的发生。总而言之，目标是 将提供关于代谢途径的新的机械性见解 推动胰腺癌的启动，从而为未来的治疗提供信息。